Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Jaguar Health Inc
(NQ:
JAGX
)
4.630
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
August 16, 2023
Via
ACCESSWIRE
Jaguar Health Reports Second Quarter 2023 Financial Results
August 14, 2023
Via
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
August 10, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
August 09, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
August 08, 2023
Via
ACCESSWIRE
Jaguar Health Subsidiary Becomes Corporate Partner of Multinational Association of Supportive Care in Cancer (MASCC)
June 20, 2023
Via
ACCESSWIRE
Canine and Child Cancer Research Advocates Call for Support as Capitol Hill "Goes to the Dogs"
June 08, 2023
Via
ACCESSWIRE
Take C.H.A.R.G.E. Registry Marks One-Year Anniversary on National Canine Cancer Awareness Day, With Database Grown 40%
May 23, 2023
Via
ACCESSWIRE
Jaguar Health Reports First Quarter 2023 Financial Results
May 15, 2023
Via
ACCESSWIRE
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
August 07, 2023
Via
ACCESSWIRE
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
August 03, 2023
Via
ACCESSWIRE
REMINDER: Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton" August 5th
August 02, 2023
Via
ACCESSWIRE
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
August 01, 2023
Via
ACCESSWIRE
In Honor of World Nature Conservation Day, Jaguar Health Announces Planting of More Than 1.1 Million Trees in Peruvian Amazon
July 27, 2023
Via
ACCESSWIRE
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
July 26, 2023
Via
ACCESSWIRE
Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug
May 10, 2023
Via
ACCESSWIRE
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
May 09, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton"
July 25, 2023
Via
ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
July 07, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease
June 28, 2023
Via
ACCESSWIRE
First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, Joins International Network to Help Advance Canine and Human Cancer Research
June 26, 2023
Via
ACCESSWIRE
Jaguar Health Launching AI-Driven Social Media Disease Awareness Education Series Regarding Cancer Therapy-Related Diarrhea in Dogs and People
June 22, 2023
Via
ACCESSWIRE
Jaguar Health to Present June 21st at MedInvest Oncology Investor Conference
June 15, 2023
Via
ACCESSWIRE
Ladenburg Thalmann to Host Virtual Discussion June 22nd with Jaguar Health CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care
June 14, 2023
Via
ACCESSWIRE
European Pharmaceutical Industry Leader and Entrepreneur Massimo Radaelli, PhD Named Commander of the Italian Republic for Special Merits
June 07, 2023
Via
ACCESSWIRE
Jaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
May 25, 2023
Via
ACCESSWIRE
Board Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board
May 24, 2023
Via
ACCESSWIRE
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
May 19, 2023
Via
ACCESSWIRE
Jaguar Health to Present at Lytham Partners Spring 2023 Investor Conference & Participate in Animal Health Panel
May 16, 2023
Via
ACCESSWIRE
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
May 11, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.